Annual report [Section 13 and 15(d), not S-K Item 405]

SHARE-BASED COMPENSATION

v3.25.4
SHARE-BASED COMPENSATION
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
In August 2021, the Company adopted the 2021 Equity Incentive Plan (as amended, the “LTIP”). The LTIP allows for awards to be granted in the form of stock options, stock appreciation rights, shares of restricted stock, other share-based awards (payable in cash or common stock) or performance awards, or any combination thereof, and may be made to outside directors, employees or consultants. As of December 31, 2025, 1,146,216 shares remained available to grant under the LTIP.
Restricted Stock Units — During the year ended December 31, 2025, the number of shares and the weighted average grant price of restricted stock unit transactions were as follows:
Number of Shares Weighted Average Grant Price
Non-vested as of January 1, 2025:
1,553,989  $ 29.12 
Granted 505,591  $ 35.53 
Vested/released (798,398) $ 32.26 
Cancelled/forfeited (69,396) $ 28.74 
Non-vested outstanding as of December 31, 2025
1,191,786  $ 29.76 
The weighted average grant date fair value of restricted stock units granted was $35.53, $26.93 and $24.35 during the years ended December 31, 2025, 2024 and 2023, respectively. The aggregate intrinsic value of the awards that vested and were released during the years ended December 31, 2025, 2024 and 2023 was $27.9 million, $13.1 million and $11.2 million, respectively. As of December 31, 2025, the Company had approximately $17.9 million in total unrecognized compensation costs associated with these awards, and the weighted average period over which it is expected to be recognized is 1.7 years.
Stock Options — During the year ended December 31, 2025, the number of stock options transactions and the weighted average grant price of stock options were as follows:
Number of Shares Weighted Average Grant Price Weighted Average Exercise Price
Outstanding as of January 1, 2025:
337,678  $ 20.03  $ 20.27 
Exercised/released (238,844) $ 18.82  $ 14.80 
Expired (20,132) $ 21.19  $ 63.56 
Outstanding as of December 31, 2025
78,702  $ 23.38  $ 25.77 
Vested and exercisable 78,702  $ 23.38  $ 25.77 
As of December 31, 2025, the Company had no unrecognized compensation costs associated with stock options. The weighted average remaining contractual term on the outstanding stock options is 4.1 years. As of December 31, 2025, the weighted average exercise price of the vested and exercisable stock options was $25.77 and had an aggregate intrinsic value of $0.9 million. The Company did not grant any stock options during the years ended December 31, 2025, 2024, and 2023.